Vascular disease, including cardiovascular disease (CVD), diabetes, obesity, tumor growth and metastasis, and severe infectious diseases such as COVID-19, arises from dysregulation of blood vessels and components of the blood.
The Irish Centre for Vascular Biology (ICVB) was formed at RCSI to act as a national research hub to facilitate world-class research between researchers, clinicians and industry partners working within the vascular biology disease space in Ireland. Consequently, it incorporates leading Irish researchers, clinicians and research groups in the areas of haemostasis, vascular inflammation, platelet biology, circadian regulation of thrombogenesis and drug design for mitigation of vascular disease.
ICVB investigators in the School of Pharmacy and Biomolecular Sciences are funded by all major Irish research funding bodies and other major international funding bodies, including the European Research Council (ERC) and National Institutes of Health (NIH). Investigators in this research area are also closely aligned with the pharmaceutical industry and have led collaborative strategic research partnerships with global pharmaceutical leaders and developed startup companies based on IP generated by ICVB investigators in the School of Pharmacy and Biomolecular Sciences.